Abstract: The invention relates to novel pharmaceutically-useful peptides, in particular cyclic peptides that are agonists of the AngII type 2 receptor (AT2 receptor). The invention further relates to the use of such peptides as medicaments, to pharmaceutical compositions containing them, and to their production.

Abstract: The invention relates to novel pharmaceutically-useful peptides, in particular cyclic peptides that are agonists of the AngII type 2 receptor (AT2 receptor). The invention further relates to the use of such peptides as medicaments, to pharmaceutical compositions containing them, and to their production.

Abstract: The invention relates to novel pharmaceutically-useful peptides, in particular cyclic peptides that are agonists of the AngII type 2 receptor (AT2 receptor). The invention further relates to the use of such peptides as medicaments, to pharmaceutical compositions containing them, and to their production.

Abstract: The invention relates to the field of pharmacology. In particular, it relates to novel analogs of apelin, and to the therapeutic uses thereof. Provided is cyclic apelin analog of the general formula X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, comprising a Lanthionine bridge of the structure Ala-S-Ala or a methylLanthionine bridge of the structure Abu-S-Ala or Ala-S-Abu and wherein said (methyl)Lanthionine bridge is of the size i, i+3; i, i+4, i, i+5 or i, i+6.

Abstract: The invention relates to novel pharmaceutically-useful peptides, in particular cyclic peptides that are agonists of the AngII type 2 receptor (AT2 receptor). The invention further relates to the use of such peptides as medicaments, to pharmaceutical compositions containing them, and to their production.

Abstract: The invention relates to the production of heterologous polypeptides in a recombinant host cell. More specifically, it relates to the production and secretion of peptides, such as biologically active peptides, that are modified by one or more lantibiotic-synthesizing enzymes. Provided is a nucleic acid construct encoding a polypeptide comprising 1) a non-lantibiotic export signal that is recognized by a non-lantibiotic export system; 2) a lantibiotic leader peptide that is recognized by at least a lantibiotic dehydratase such as LanB and, C-terminally of said export signal and said leader peptide, 3) a peptide of interest containing one or more serine or threonine residue(s) which can be posttranslationally dehydrated by said dehydratase.

Abstract: The invention relates to analogs of angiotensins, in particular to cyclised analogs having Ang(1-8) agonistic or antagonistic activity and to cyclised Ang(1-7) analogs with agonistic or antagonistic activity and displaying improved proteolytic resistance compared to their linear counterparts. Provided is a cyclic angiotensin peptide analog comprising a thioether-bridge linkage between the amino acids corresponding to positions Tyr4 and Pro7 in naturally occurring Angiotensin. Also provided is the use of analogs in therapy, for example hypertension.

Abstract: The invention relates to novel pharmaceutically-useful peptides, in particular cyclic peptides that are agonists of the AngII type 2 receptor (AT2 receptor). The invention further relates to the use of such peptides as medicaments, to pharmaceutical compositions containing them, and to their production.

Abstract: Described are novel ways of introducing an affinity tag into a protein of interest. Provided is an enzymatic method for providing a proteinaceous substance comprising a polypeptide of interest and a cyclic affinity tag, comprising: (a) providing at least one precursor proteinaceous substance, the precursor comprising the protein of interest and at least one motif of the general formula X1-Tag-X2, wherein X1 and X2 represent amino acids whose side chains can be linked enzymatically by a covalent bond; Tag is a short amino acid sequence capable of binding to a binding partner of the tag when cyclized; (b) contacting the precursor with at least one enzyme capable of forming a covalent bond between X1 and X2, thereby introducing an intramolecular ring structure comprising the Tag sequence; and (c) isolating the resulting cyclized proteinaceous substance. Also provided are proteinaceous substances obtainable thereby and the use thereof, for instance, for preparing a peptide library.

Abstract: The invention relates to analogs of angiotensins, in particular to cyclised analogs having Ang(1-8) agonistic or antagonistic activity and to cyclised Ang(1-7) analogs with agonistic or antagonistic activity and displaying improved proteolytic resistance compared to their linear counterparts. Provided is a cyclic angiotensin peptide analog comprising a thioether-bridge linkage between the amino acids corresponding to positions Tyr4 and Pro7 in naturally occurring Angiotensin. Also provided is the use of analogs in therapy, for example hypertension.

Abstract: The invention relates to the production of heterologous polypeptides in a recombinant host cell. More specifically, it relates to the production and secretion of peptides, such as biologically active peptides, that are modified by one or more lantibiotic-synthesizing enzymes. Provided is a nucleic acid construct encoding a polypeptide comprising 1) a non-lantibiotic export signal that is recognized by a non-lantibiotic export system; 2) a lantibiotic leader peptide that is recognized by at least a lantibiotic dehydratase such as LanB and, C-terminally of said export signal and said leader peptide, 3) a peptide of interest containing one or more serine or threonine residue(s) which can be posttranslationally dehydrated by said dehydratase.

Abstract: The present invention relates to a method of non-covalently binding a compound to a sensor surface. The method comprises adsorbing a hydrophobin-like substance to at least a part of the sensor surface, such as an electrode. The invention further provides a sensor having a surface, at least a part of which is provided with a coating of a hydrophobin-like substance that comprises a non-covalently bonded compound.

Abstract: The invention relates to methods for coating objects with hydrophobins. Provided is a method for providing the surface of an object with a hydrophobin coating, comprising contacting at least a part of an object with a hydrophobin-containing solution to form a hydrophobin layer on the surface of the object and exposing the layer to a pH below 7, preferably below 4, more preferably below 2, optionally in the presence of a detergent. Contacting can be performed at around room temperature and the hydrophobin-containing solution can be a supernatant of a culture medium of an organism that secretes a hydrophobin.

Abstract: The present invention relates to a method of binding a compound to at least a part of a surface of an object, the method comprising the step of adsorbing a hydrophobin-like substance to the surface. The invention provides a method of providing a surface of an object with a reactive compound comprising the steps of coating at least a part of the surface of the object with a coating of a hydrophobin-like substance and contacting the compound with the coated hydrophobin-like substance to form a non-covalent bond between the hydrophobin-like substance and the compound.

Abstract: The present invention relates to a method of non-covalently binding a compound to a sensor surface. The method comprises adsorbing a hydrophobin-like substance to at least a part of the sensor surface, such as an electrode. The invention further provides a sensor having a surface, at least a part of which is provided with a coating of a hydrophobin-like substance that comprises a non-covalently bonded compound.

Abstract: An isolated microorganism capable of selectively degrading epichlorohydrin or related halopropanol compounds is described. The microorganism is a representative of Agrobacterium spp and comprises a nucleic acid molecule encoding a polypeptide having enantioselective epoxide hydrolase activity.